08:00 , Jan 23, 2012 |  BC Week In Review  |  Financial News

Arrogene completes venture financing

Arrogene Nanotechnology Inc. , Los Angeles, Calif.   Business: Cancer, Drug delivery, Diagnostic   Date completed: 1/18/12   Type: Venture financing   Raised: $500,000   Placement agent: WestPark Capital  ...
08:00 , Feb 24, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer HER2 (ERBB2; neu); transferrin receptor Mouse studies suggest that a nanopolymer-based conjugate could help treat HER2-positive breast cancer. A...
08:00 , Jan 24, 2011 |  BioCentury  |  Emerging Company Profile

Arrogene: Slick chemistry from slime

Most polymer-based nanoparticles in development to deliver cancer drugs are not covalently bound to the drug. These products carry risks of toxicity because the therapeutic agent could be released early if the nanoparticle degrades before...
07:00 , Nov 4, 2010 |  BC Innovations  |  Cover Story

LAMbasting brain cancer

Approved therapies to treat brain cancer are not entirely tumor cell-specific and thus can have severe dose-limiting toxicities that decrease their effectiveness. A team of U.S. and German researchers thinks it has overcome this problem...
07:00 , Oct 14, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer Transferrin receptor; laminin a4 (LAMA4); laminin b1 (LAMB1) In vitro and mouse studies suggest that a nanopolymer-based conjugate could...